Loading company…
Saiaowei develops nucleic acid nanoparticle drugs and therapies for chronic diseases and regenerative medicine.
Founded in 2020 and based in Shenzhen, China, Saiaowei develops synthetic biology technologies and nucleic acid nanoparticle drugs. It also provides development services for major chronic diseases and regenerative medicine therapies. In July 2024, it received strategic investment from Leaguer Group.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in